Maven Scotland’s Post

👩🔬📰 Delighted to see our investee, BioAscent, featured in Insider.co.uk! The article explores its remarkable journey to becoming a driving force in Scotland's biotech resurgence. Its story is a testament to resilience and innovation. The state-of-the-art biosciences hub it operates from was once at risk of being lost to history, but is now at the forefront of a biotech renaissance in Scotland, thanks to strategic vision, skilled leadership and investment. Since Maven’s VCT investment in 2018, the company has scaled significantly and expanded into a fully integrated drug discovery CRO. Read the Insider article in full here 👇 https://hubs.ly/Q02ZJtFJ0 #DrugDiscovery #LifeSciences #Innovation #VCTs #VentureCapital #BioTech

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #2. We have resilience of spirit: When we hit a stumbling block, our ingenuity helps us remain agile and allows us to find new ways towards our goals. In the spirit of continuous learning and improvement, we accept that not everything will work first time, and we learn from any failures. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Explore how biotechs can unlock early value in their commercial journey and look ahead to a brighter future at the 2024 Fierce Biotech Summit. Don’t miss our presentation in the Strategy and Dealmaking track at 2:30pm on September 30. #commercialsuccess #biotech #innovation Karla Anderson, Maya K. Desai, PhD, Michele Fuller

📢 𝗢𝘂𝗿 𝗼𝟮𝗵 𝗵𝘂𝗺𝗮𝗻 𝗵𝗲𝗮𝗹𝘁𝗵 𝗦𝗘𝗜𝗦 𝗳𝘂𝗻𝗱 𝗶𝘀 𝗡𝗼𝘄 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁!   The o2h human health SEIS fund is accepting applications for investment until January 31st, 2025, offering access to a pipeline of promising opportunities in #biotech. We invest in pure-play therapeutics, biotech enablers, and the convergence of biotechnology with AI/ML, and the minimum investment starts at £10,000 for backing at least three pre-seed or seed-stage biotech companies.   👉 To learn more about the benefits of investing in SEIS and for more details on the exciting deal opportunities we're exploring, 𝙥𝙡𝙚𝙖𝙨𝙚 𝙘𝙤𝙣𝙩𝙖𝙘𝙩 𝙪𝙨 𝙖𝙩 𝙞𝙣𝙫𝙚𝙨𝙩@𝙤2𝙝.𝙘𝙤𝙢. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong. #o2hVentures #seedingnewideas #eis #seis

💰BIO Roundup: Deal-Making Tips And Tricks • WHO SHOULD READ THIS? BD&L professionals in small companies looking for larger partners or investors. • WHAT IS IT? A round-up of insights gathered by Citeline News & Insights reporters from panel discussions and in exclusive interviews at the BIO International Conference on the subject of deal-making. • WHY IS IT IMPORTANT? Biotech companies are competing for the attention of potential partners to fund their R&D and help them achieve commercial success. This feature highlights key advice on decision-making, ranging from pipeline strategy to approaching international markets. Citeline Citeline Commercial #BIO2024

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #6. We are focused: To ensure alignment with our mission, we take a focused approach to our delivery. We wisely utilise our resources and pay attention to our priorities. We balance pursuing our ambitious goals and innovations with our ability to ”focus and finish”. We focus on our most important work, and we are clear on our daily priorities to deliver our collective goals and mission. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

"Have you thought about building SHRMP.bio somewhere else? Are you dependent on backing from Australia?"   Since the beginning, we have been asked these questions, often by partners who reflected on the "deeptech" and biotech vision behind SHRMP.bio, along with the associated time and capital needs, and who then flagged that there may be a potential cultural misalignment with Australia.   *No, we have not* - and here is why not:   Maybe surprisingly, it has been our Australian experience that triggered our interest in the Blue Economy and the concept of SHRMP.bio.  Australia, with its extensive coastline and harsh environments, is uniquely positioned to develop *technologies* with significant export potential.  We boast excellent R&D institutions and a thriving entrepreneurial ecosystem, making it an ideal ground for innovation. The Blue Industry represents a key growth area that could be leveraging Australia's geographical advantages.  And even if the Blue Economy doesn’t capture attention, SHRMP.bio combines both, biotechnology and high-tech (modern) manufacturing, sectors regularly featured in government and media discussions.  For these reasons alone, Australia should be the perfect home for SHRMP.bio. Read more here: https://lnkd.in/g35FX--H

#Biotech funding is a hot topic! This week, Mediar CEO Rahul Ballal, PhD, will share his perspectives during two panel discussions. First up this afternoon is "Fueling the Future: CEO Perspectives on Funding Clinical-Stage Biotechs" with Clinical Outsourcing Group New England, a conversation with biotech leaders about strategies for financing clinical pipelines, including international trends in venture capital, public markets, licensing deals, local government funding, and cross-border partnerships. Rounding out the week on Thursday is "Cautious Optimism? State of Biotech Funding in 2024" at MassBio Align Summit, discussing the evolving opportunities and headwinds across the funding landscape, how to effectively respond to challenges, and ways to capitalize on market trends to support innovations We look forward to sharing our insights and connecting with other #biotech pioneers for these important discussions. #COGNewEngland #AlignSummit24

Excited to share McKinsey’s latest report on the European biotech financing landscape based on our presentation at Bio€quity Europe 2024 a few weeks back. My key takeaway from the report? The biotech industry started 2024 with some positive trends on financing and these trends are bringing a sentiment of cautious optimism to both biotech companies and investors. Check out the infographic below for other key takeaways and read the report for more strategic implications and insights for investors and biotech companies alike: https://lnkd.in/eMJkZJ2z #Biotech #BiotechInvestments #FutureOfBiotech #BioEquity

Excited to share McKinsey’s latest report on the European biotech financing landscape based on our presentation at Bio€quity Europe 2024 a few weeks back. My key takeaway from the report? The biotech industry started 2024 with some positive trends on financing and these trends are bringing a sentiment of cautious optimism to both biotech companies and investors. Check out the infographic below for other key takeaways and read the report for more strategic implications and insights for investors and biotech companies alike: https://lnkd.in/d-6atERy #Biotech #BiotechInvestments #FutureOfBiotech #BioEquity